skip to Main Content

IWGDF Guideline Recommendation

The International Working Group on the Diabetic Foot (IWGDF) now recommends the use of 3C Patch® as an adjunctive treatment.49 The guideline recommendation is published in the new guidelines on The Prevention and Management of Diabetic Foot Disease.

IWGDF Guideline

The guideline recommendation is based on Reapplix’s substantial body of evidence supporting the use of 3C Patch®, including the Randomised Controlled Trial recently published in The Lancet Diabetes & Endocrinology.1

The Lancet publication

3C Patch® is cleared by the FDA for the management of exuding wounds, such as leg ulcers, and diabetic ulcers and mechanically or surgically debrided wounds.

The product is also CE marked in Europe. The intended use of the product is to produce an autologous platelet-rich fibrin for wound management of recalcitrant wounds.

3C Patch® will be the new name for Leucopatch® during 2019 in Europe.

DFU Challenge

Biological Science

3C Patch® System

Clinical Practice

FAQ

Back To Top